Compare GWH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | AYTU |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 27.4M |
| IPO Year | N/A | 2015 |
| Metric | GWH | AYTU |
|---|---|---|
| Price | $0.86 | $2.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.25 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 764.2K | 23.4K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.72 | $1.65 |
| 52 Week High | $13.87 | $3.07 |
| Indicator | GWH | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 45.37 |
| Support Level | $0.73 | $2.08 |
| Resistance Level | $1.15 | $2.32 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 37.47 | 33.39 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.